Auxier Asset Management increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,773 shares of the biopharmaceutical company’s stock after acquiring an additional 96 shares during the quarter. Auxier Asset Management’s holdings in Gilead Sciences were worth $479,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Schafer Cullen Capital Management Inc. purchased a new stake in Gilead Sciences during the second quarter valued at $284,000. Cullen Capital Management LLC purchased a new stake in Gilead Sciences during the second quarter valued at $566,000. Colony Group LLC purchased a new stake in Gilead Sciences during the second quarter valued at $229,000. Keel Point LLC raised its stake in Gilead Sciences by 0.4% during the second quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 12 shares in the last quarter. Finally, National Asset Management Inc. raised its stake in Gilead Sciences by 0.7% during the second quarter. National Asset Management Inc. now owns 26,270 shares of the biopharmaceutical company’s stock valued at $1,862,000 after purchasing an additional 174 shares in the last quarter. Hedge funds and other institutional investors own 76.23% of the company’s stock.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $76.09 on Wednesday. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The company has a market cap of $96,951.29, a PE ratio of 7.75, a PEG ratio of -1.24 and a beta of 1.13. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.75 earnings per share. research analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.73%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s payout ratio is presently 23.69%.

A number of equities research analysts recently issued reports on the stock. Mizuho reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Friday, September 29th. Maxim Group set a $94.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Monday. Berenberg Bank reaffirmed a “buy” rating and set a $86.00 price target (up previously from $79.00) on shares of Gilead Sciences in a research note on Sunday, August 20th. Credit Suisse Group reaffirmed a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a research note on Thursday, December 7th. Finally, Cowen reaffirmed an “outperform” rating and set a $90.00 price target on shares of Gilead Sciences in a research note on Thursday, August 31st. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $85.11.

In other news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $74.98, for a total value of $5,498,508.34. Following the transaction, the insider now directly owns 3,070,099 shares in the company, valued at $230,196,023.02. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the completion of the transaction, the executive vice president now owns 70,988 shares in the company, valued at $5,298,544.32. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 494,999 shares of company stock worth $37,404,139. Company insiders own 1.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/13/auxier-asset-management-raises-position-in-gilead-sciences-inc-gild.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related stocks with our FREE daily email newsletter.